Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck

Biotech’s Fortunes Riding On Other Assets

Executive Summary

Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.

You may also be interested in...



Finance Watch: The Job Cuts Keep Coming As Companies Try To Conserve Cash

Restructuring Updates: Homology implemented modest job cuts as it ended a gene therapy trial, while ProQR revealed its second round of layoffs this year and Synthetic Biologics shifted focus to oncolytic virus pipeline. Also, Bolt, MacroGenics and others deprioritized programs in their Q2 updates.

Bayer Sells Nebido To Grünenthal Amid Shift In Focus To Cell And Gene Pipeline

The major will use funds from the sale of its male hypogonadism product to invest in future innovation, which is likely to focus on high-risk high-reward cell and gene drug candidates.

Bayer Banks On Boston To Achieve Oncology Ambitions

The German major is investing heavily in cancer R&D and has opened the doors of a new facility in the biotech epicenter on the east coast of the US.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel